STAAR Surgical Co. - Form 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 29, 2002. STAAR Surgical Company develops, manufactures, and distributes medical devices for minimally invasive ophthalmic surgery, primarily in the cataract, refractive, and glaucoma segments. The company operates manufacturing sites in the United States and Switzerland and markets products in over 40 countries.
Key Financial Metrics
| Metric (in thousands) | Q1 2002 | Q1 2001 |
|---|---|---|
| Total Revenues | $11,731 | $13,001 |
| Gross Profit | $5,712 | $7,822 |
| Gross Margin | 48.7% | 60.2% |
| Operating Loss | $(1,768) | $(346) |
| Net Loss | $(997) | $(230) |
| Net Loss Per Share | $(0.06) | $(0.01) |
| Cash from Operations | $501 | $(2,287) |
| Cash and Equivalents (End of Period) | $764 | $4,027 |
| Notes Payable | $7,769 | $8,216 |
| Current Ratio | 2.0:1 | 1.9:1 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 9.8% to $11.7 million. This was driven by decreased sales from foreign subsidiaries closed in 2001, lower average selling prices for Elastic silicone IOLs, and reduced unit sales of Elastimide silicone IOLs and Collamer IOLs in the U.S. Partial offsets included increased sales of the AquaFlow Glaucoma Device and STAARVISC II.
- Margin Compression: Gross margin fell to 48.7% from 60.2%. The decline is attributed to lower revenue volumes and higher unit costs for silicone IOLs due to reduced production levels.
- Expense Trends:
- Marketing & Selling: Decreased by approximately $1.1 million (21.4% reduction) due to the elimination of the Sonic WAVE direct sales force costs and timing of trade shows.
- R&D: Increased by $258,000 (31.6% increase) to support the development of the Sonic WAVE Phacoemulsification System.
- G&A: Increased by $143,000, largely due to lower revenue base, higher utility/insurance costs, and professional fees, partially offset by the cessation of goodwill amortization.
- Working Capital: Inventories decreased by $1.3 million due to improved inventory management. Cash from operations turned positive ($501k) compared to a significant outflow in the prior year.
Guidance, Outlook, and Risks
- Outlook: Management expects to be profitable in the future and believes current cash balances, credit facilities, and operating cash flow are sufficient to fund operations.
- Debt Facility: The line of credit was amended on March 29, 2002, extending maturity to March 31, 2003. Interest rates are prime plus a spread (1%-4%) based on funded debt to EBITDA ratios. The agreement includes covenants and minimum cash balance requirements.
- Tax Benefit: Legislation enacted in March 2002 allows the company to carry back losses to 1996-1998, resulting in an expected tax refund of approximately $959,000 recorded as a benefit in this quarter.
- Risks:
- Legal: Ongoing litigation with former CEO John R. Wolf regarding wrongful termination and stock options.
- Foreign Exchange: The company does not hedge foreign currency; fluctuations may adversely impact export sales.
- Interest Rate: Exposure to interest rate changes on bank borrowings (estimated $25,000 cash flow impact per 100 basis point increase).
Investor Verification Checklist
- Verify the realization of the $959,000 income tax refund receivable.
- Monitor compliance with the amended credit facility covenants, specifically the funded debt to EBITDA ratio and minimum cash balances.
- Assess the progress and commercial viability of the Sonic WAVE Phacoemulsification System given increased R&D spend.
- Review the status of the legal proceedings against former CEO John R. Wolf.
- Confirm the trend in inventory levels and whether the reduction to $13.98 million is sustainable without impacting sales.